<SEC-DOCUMENT>0001104659-21-049955.txt : 20210414
<SEC-HEADER>0001104659-21-049955.hdr.sgml : 20210414
<ACCEPTANCE-DATETIME>20210414070140
ACCESSION NUMBER:		0001104659-21-049955
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210414
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210414
DATE AS OF CHANGE:		20210414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		21824510

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2112893d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):</B>
April 14, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices) (Zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; border: black 1pt solid; padding-right: -0.9pt; padding-left: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: -0.9pt; padding-left: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 18pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 14, 2021, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing that enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial
of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease
(aGVHD). The single-center, randomized, double-blinded, placebo-controlled clinical trial will evaluate the safety, tolerability and potential
absorption into the systemic circulation (if any) of 150 mg oral SYN-004 administered to allogeneic HCT recipients who receive an IV beta-lactam
antibiotic to treat fever. Study participants will be enrolled into three sequential cohorts, with each receiving a different study-assigned
IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 and four will receive placebo. A data readout for the
first cohort is anticipated towards the end of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01 and&nbsp;in the press release attached
as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 shall not be incorporated
by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The press release attached as Exhibit 99.1 includes &ldquo;safe harbor&rdquo;
language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein
are &ldquo;forward-looking&rdquo; rather than historical.&nbsp;The Company undertakes no duty or obligation to update or revise the information
contained in this&nbsp;Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate.
Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press
releases or through other public disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 14, 2021, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing that enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial
of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease
(aGVHD). A data readout for the first cohort is anticipated towards the end of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center"></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="tm2112893d1_ex99-1.htm">99.1</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="tm2112893d1_ex99-1.htm">Press
    Release issued by Synthetic Biologics, Inc., dated April 14, 2021</A></FONT></TD></TR>
  </TABLE>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 18pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April 14, 2021</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 38%; padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">Chief Executive Officer and Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 18pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2112893d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2112893d1_image001.jpg" ALT="" STYLE="width: 214pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients </B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, April 14, 2021 &ndash;</B></FONT> Synthetic Biologics, Inc. <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a diversified
clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases
in areas of high unmet need, <FONT STYLE="color: windowtext">today announced enrollment has commenced and the first patient has been dosed
in its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention
of acute graft-versus-host-disease (aGVHD). </FONT>Broad spectrum intravenous (IV) beta-lactam antibiotics used to treat infection following
conditioning chemotherapy for allogeneic HCT patients is a necessary and oftentimes lifesaving intervention. However, a<FONT STYLE="color: windowtext">ntibiotic-mediated
damage of the gut microbiome in this patient population has been strongly associated with adverse outcomes including <I>C. difficile </I>infection
(CDI), vancomycin-resistant enterococci (VRE) colonization, potentially fatal bacteremia, and aGVHD.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;Allogenic HCT recipients are at very
high risk for infection and frequently receive antibiotics,&rdquo; said Erik Dubberke, MD, Professor of Medicine and Clinical
Director of Transplant Infectious Diseases at Washington University School of Medicine in St. Louis. &ldquo;There is increasing
evidence that disruption of the microbiome caused by antibiotics results in additional complications, including further infections.
If this trial shows that SYN-004 has a favorable safety profile and is able to protect the microbiome, it would warrant study in
larger trials to determine if this treatment can improve outcomes in these highly susceptible patients<B><I>.</I>&rdquo;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;We are very excited to begin enrollment
of our SYN-004 Phase 1b/2a clinical trial in allogeneic HCT recipients,&rdquo; said Steve A. Shallcross, Chief Executive Officer of Synthetic
Biologics. &ldquo;We are very grateful for the tremendous support from Dr. Dubberke and his team at Washington University. This clinical
program is a critical component of our efforts to expand and fortify the already well-established dataset for SYN-004 and our pursuit
of a cost-effective development strategy in a highly specialized patient population. We look forward to reporting key clinical milestones
as we advance the trial.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">The single-center,
randomized, double-blinded, placebo-controlled clinical trial will evaluate the safety, tolerability and potential absorption into the
systemic circulation (if any) of 150 mg oral SYN-004 administered four times per day to allogeneic HCT recipients who receive an intravenous
(IV) beta-lactam antibiotic to treat fever. </FONT>Study participants will be enrolled into three sequential cohorts, with each receiving
a different study-assigned IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 and four will receive placebo.
A data readout for the first cohort is anticipated towards the end of 2021.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The study will also evaluate potential protective
effects of SYN-004 on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes
of SYN-004 in allogeneic HCT recipients. Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety
Monitoring Committee, which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will serve as the sponsor
of the clinical trial and supply SYN-004 to Washington University. Dr. Dubberke will serve as the principal investigator along with his
Washington University colleague, Dr. Mark A. Schroeder, Associate Professor of Medicine, Division of Oncology, Bone Marrow Transplantation
and Leukemia.</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 18pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About the SYN-004 (ribaxamase) Phase 1b/2a
Clinical Trial</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">SYN-004 (ribaxamase) is an oral prophylactic therapy
designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for
the prevention of <I>Clostridioides difficile</I> infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial
resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic
HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection following conditioning therapy. Antibiotic-mediated
damage of the gut microbiome in allogeneic HCT recipients may lead to adverse outcomes including CDI, VRE colonization and potentially
fatal bacteremia and aGVHD. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected
the gut microbiome from antibiotic-mediated dysbiosis. Patients who received SYN-004 also demonstrated significantly better maintenance
and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms
such as VRE.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade
certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage,
(b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance
(AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020,
a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat
both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>This
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
 &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and
similar expressions, and includes statements regarding a data readout from the first cohort towards the end of 2021, the potential of
SYN-004 to significantly improve outcomes for allogenic HCT recipient and the intended benefits to be derived from SYN-004 and SYN-020.
These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are
subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially
from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could
cause actual results to differ materially from current expectations include, among others, Synthetic Biologics' ability to provide data
towards the end of 2021, the ability to continue to comply with continued listing requirements of the NYSE American, the ability of its
product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic Biologics'
clinical trials continuing and/or beginning enrollment as expected, a failure to receive the necessary regulatory approvals for commencement
of clinical trials and commercialization of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a failure
of Synthetic Biologics' clinical trials, and those conducted by investigators, for SYN-004 and SYN-020 to be commenced or completed on
time or to achieve desired results and benefits, a failure of Synthetic Biologics' clinical trials to continue enrollment as expected
or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics'
inability to maintain its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully
commercialize products, Synthetic Biologics&rsquo; ability to achieve acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete
or non-competitive, the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and remaining
profitable, Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and development activities,
a loss of any of Synthetic Biologics' key scientists or management personnel and other factors described in Synthetic Biologics' Form
10-K for the year ended December 31, 2020 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and
8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except
as required by law.</I></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, gregory.kelley@ogilvy.com</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"># # #</P>



<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 18pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2112893d1_image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2112893d1_image001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #C F # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6P_-&:9FMGP_I(U*X:2;/V>+&1_>/I6M##SKU%3ANR*LXTX.<MD4+>RNKO\
MU$$D@]57C\Z?/IM[;)OFM954=6VY KT-$2- B*%51@ # %.KZ-</4^76;O\
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MZ;;Z/I5KIUJ@6&WC"* .N.I/N3S^-5*7*M!17-N?+NM^%]:\.,@U;3Y+8/\
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M?4E?(>H_\A.[_P"NS_\ H1KZ\KY%U6-HM8O8W&&2XD4CW#&II=1U#V'X%_\
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MS)U$3C."1Z'.#^%4V[71*6MF9G_"LO&/_0$D_P"_T?\ \51_PK+QC_T!)/\
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M?:-\PBV^9LQD$YS@^E6=#U3^VM'@U#R?)\W=^[W;L88KUP/2N>^)7_(N6_\
MU]K_ .@/6AX'_P"1.L/^VG_HQJQ527UET[Z6.N5"FLOC6M[SDU?R.AJAJ^LV
M>B6?VF\D*J3A5499SZ 5?KS3XFNQU*QC)^582P'N3S_(5>)JNE2<UN99?AHX
MG$1IR>G^1K1_$K3&E"O:72(3]["G'X9KK[2[@OK6.YMI!)#(-RL.]<GXD\/:
M7;^#YGM[*&*6"-&654&_J,Y/4YYZTOPWE=_#\\;'*QW!"^P*J<?GG\ZQI5*L
M:JIU&G=7T.G$8?#3PSQ&'35G9INYV-8OB#Q+:^'?L_VF&:3S]VWRP.-N,YR1
MZUM5Y[\4/^85_P!MO_9*UQ525.DYQW.;+J$*^)C3J;._Y'=V=RE[8V]TBE4G
MC610W4!AGG\ZGK/T#_D7-,_Z](O_ $ 5H5M!WBFSEJQ49RBNC?YL*YS6O&>F
M:+<FU<23W"_>2(#"_4DUT=>4^%K2#5_&ET;Z)9E_>RE7&06W=QWZUSXFK.+C
M"&\F=V P]*HJE6M?E@KV74Z_2/'6EZK=I:E9;>5SA/- VL?3(/6NGKRGQ[86
MNF:U;/8PK;[X@Y6(;0&!/( Z5ZI&2T2,>I )HP]6<I2A4WB/'8>C"%.M1NE-
M/1]+#JP-<\7Z;H4PMYO,FN,9,<0'RCMDGI6_7E6F6T6K_$:X2]42Q^?,Q1N0
M=N<#Z#C\J>)JSARQAO)V)R_#4ZKG.K\,%>RZG6:3X\TO4[Q+5DEMI)#A#+C:
MQ],@]:ZFN&\2^!WO;V&XT:.UM@%Q(H.P9!X( %=M")!!&)<>9M&_!XSCFG0E
M5NXU>G7N3C(8;EC4P[WW3=VA]<M>^,OL?BI=$^P;]TT47G>=C[X7G;M[;O7M
M74UY;K7_ "5.+_K[MOY)4XNI*G&+B]VC3+:%.M.:J*]HM_,]2HHHKJ/-.<UK
MQIIFBW)M7$D]POWDB POU)/6F:1XYTO5KI+7;+;3.<()0,,?0$'K]:X_PI:6
M^J^,KK[=$LX EEVN,@MN'4=^IK;\1>!Y[K5(KK14MK50HW+G8 X/4 #CM^5>
M=&MB)KVD+-7M;J>_4PF!I26'J-J5K\U]+^AW=%(N=HW8SCG%+7HG@'/:WXRT
MW1+C[-())[@#+)$!\OU)J+1_'&EZO=+:[9;>9^$$H&&/H"._UKAY9(=-\>SR
MZS 981<NS*PW @YVMCN.0<5UTWA31M?O(M4T^\$,6!N%H ,L#D'_ &3^%>="
MO7J2?+;1[=;'O5<'A*-.*J*7O*_,M5?M8["B@=**]$\$*BN;>.[M9;>49CD4
MJWT-2T4FDU9C3:=T>,7UI)87TUK*,/$Q4^_H?Q'-09KO?'.BF>W&J0+F2(;9
M@.Z^OX?R^E>?9KY+%X=T*KATZ>A]I@\0L114UOU]23-&:CS1FN:QU6),TJ2-
M&X=&*L#D$'!%19HS0'*='8^,M6LP%>1;E!VF&3^8Y_/-=3HWC*VU.Z6VGA-M
M*_"DOE6/IGC!KS/-&ZNZCCZ])K6Z[,X*^68>JG[MGW1[E17EVG^--5L8Q$S)
M<H.!YP)8#ZC^N:GN?'FJ31E(4@@)_B523^O'Z5ZZS6ARW=[]K'BO)L2I65K=
M[G1^,M9CLM->QC8&YN!M(!^ZG<GZ]*\XS22SR3RM+-(TDC'+,QR2:9FO$Q>(
M>(J<ST70][!X18:GR+5]23-&:CS1FN6QUV),UW7P^C(@OY>S,B_D#_C7 YKU
M'P7:&U\.Q.PPT[F4_3H/T _.O1RN%\0GV3_R/+S>2CAFN[7^9T->2^(G\WQ'
M?;.?WI7CGD<5ZRS!%+,<*!DD]A7GOA73&UC6YM6G0^1'*9 #_$Y.1^77\J]/
M,:;K<E*.[9Y65SC152M+9+\3K_#VF?V5HT,#+B5AOE_WCV_#@?A6I117HP@H
M148[(\RI-U)N<MV%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <'\3O\ CST__KH_\A69-X+M/^$035X;F87'V83NCD%#QD@8&1^M
M=!X\TB_U>VLDL+<S-&[%@& P"!ZFN=.D>-;S3X],DC9;-5"!"\:@*.F2.3^M
M>57A>M-R@W=:>I]-@JML+24*JC9MN[Z7['1_#_5;G4=(E@N6WFU8(CGKM(X!
M^F*ZZL+PKX?_ .$?TPPO()+B5M\K+T!Q@ >P_K6[7?AXRC2BI[GAXZ=.>(G*
ME\+9QWQ*_P"1<M_^OM?_ $!ZT/ __(G6'_;3_P!&-57X@6ES>Z#!':V\T\@N
ME8K$A8@;6YP/J*O>#K>:U\*64-Q#)#*N_<DBE6'SL>0:PBG];;\CLG*/]F1C
M?7F9NUYE\3/^0M9?]<#_ .A&O3:Y7QIX9FUV"&>S*_:H,C8QQO4]L^N?YFKQ
MD)3HM1W,LJK0HXJ,INRU_$M^*CCP9>Y_YXK_ #%9/PT_Y =U_P!?)_\ 05K!
MFT[QMJ-HFFW$<S6PP,.4 P.F6ZG'XUWGAO11H6C1VA8/*27E9>A8^GX #\*R
MIN56NJG*TDK:G57C##8*5'G4I2E?370UZ\]^*'_,*_[;?^R5Z%7&>/M%U#5_
M[/\ L%L9O*\S?A@,9VXZGV-:XR+E0DDK_P##G+E4XPQ<)2=EK^3.CT#_ )%S
M3/\ KTB_] %:%>9P0^/K:WC@A658HE"(O[K@ 8 KT:T\W['!Y^?.\M?,S_>Q
MS^M5AZO.K<K5K;D8W#*E+G4U*[>SOYZ_>35Y?X#_ .1QNO\ KE)_Z$*]0KSC
M5O"VMZ7KTFIZ%EUD=G&PC<F[J"#U'YUGBHRYH5$KV9OELX.%6C*2BYK1O8A^
M)G_(6LO^N!_]"->E0_ZB/_='\J\UM_"_B'Q!J\=SK@9(EP':0J"5'\*JO_UN
MM>F@8&!2PJDYSJ-63[CS&4(T:5",E)Q3O;;4*\O\-$#XD7 )P3-< ?\ CU>H
M5Y[X@\*ZO:Z^VL:)\Q=S)A& 9&/7@\$'G\^E/%QE[DXJ_*Q99.'[VE.5N>-D
MWM<QO$/_  D6A7*"YUBYQ.69!%=.< 'OTQUKU+3F9]+M'=BS-"A+$Y).T5YG
M>^&_%>MH]]?H7FC 1(W*JS#/8#  [UZ;81O#IUK%(-KI"BL/0@#-1A%)3D[-
M)[7-LTE!T:<4XN2O?EMV+%>6ZU_R5.+_ *^[;^25ZE7F^KZ9?R?$F.ZCL;E[
M875NQF6)BF $R<XQQ@U6-3<8V[HRRB48U*EW;W6>D4445VGDGE_@/_D<;K_K
ME)_Z$*['7O%EGX?N8H+F">1I$W@Q@<#..YKEM4\+:YI.O2:CH6YT=BZE"NY,
M]5(/4?G4=KX6U_7]8CN]=!2)<;VD*Y91_"JKT_3K7E4Y5J4'2C%\U]^A])7I
MX7$55B:DUR<JTOK=(]+5MR!AT(S2T45ZI\V<[J5KX=\43?8WN(9;M%)5X'!=
M .O(X[]#7"74&H^!->C,,_F1. P(X65<\AAZ_P#ZZV=9\*:MINN'5= !8,Q<
M*I :,GJ,'@CFJZ^&O$7B358Y];!AA3"LS;0=OHJCO[FO)K*<Y:0:FGHUM;U/
MIL(Z5*&M5.DUK%[W[)?U^IZ5&XEB21>C ,/QIU(JA5"J, # %+7K'S+\@HHH
MH 1E5U*L 5(P0>XKRSQ5X>?1KPS0J392GY#_ '#_ '3_ $KU2H;JU@O;:2VN
M8Q)$XPRFN7%X6.(A9[K8[<#C)86IS;I[H\0S1FMKQ'X:N-#N"ZAI+)C\DOI[
M-Z'^=8.:^9J4I4Y.,E9GV5*I"K!3@[IDF:,U'FC-18TL29HS4>:,T6"Q)FC-
M1YHS18+$F:,U'FC-%@L29HS4>:,T6"Q?TRQDU/4H+.+[TK8)_NCN?P%>SPPI
M;P1PQ+MCC4*H] !@5RO@G0&T^T-_<IBYG7"*1RB?XG_"NMKZ++L-[*GS2W?Y
M'R6;8M5JO)%Z1_/K_D4]5AFNM.EMH#M><>67/\"GJ?RS^-265E!I]G%:VZ;8
MHQ@#U]S[U8HKOY5S<W4\SGER<G3<****H@**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!DT,=Q"\,T:R1N,,K#((KSWQ!X$E@+7.D RQ=3;D_,O^Z>X]NOUK
MT6BL*^'IUU::.K"XRKAI<U-_+HSP1PT;E'4JRG!4C!!INZO:-7\.:;K2YNH,
M2XP)H_E<?CW_ !S7#ZG\/-0MRSZ?,EU'V1OD?]>#^8KQ:V758:QU1]/ALWP]
M96G[K\]OO_S./W4;JFO-.OM/;;=VDT/.,NA /T/0U5W5Q.#3LT>K%QDKQ=T2
M;J-U1[J-U*P[$FZC=4>ZMG2_"^KZL5,%JT<1_P"6LORKC^OX9JH4I3=HJY%2
M=.E'FF[+S,K.:[WPEX.<O'J.J1[0,-% PY)[%A_2MK0?!=CHY6>8_:KL<AV'
MRI_NC^I_2NFKV,)EW*^>KOV/F\PSCG3IX?;J_P#+_,****]4^?"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $90P(8 @]0:S;C
MP]HUR29=,M2QZL(PI/XBM.BIE&,MU<N%2<-8MKT9SK^!O#SG/V J2<_+,_\
MC0G@;P\C9^PEL=FF?'\ZZ*BL_J]+^5?<;?7<3M[1_>RA::)I=B0UM86\;#^(
M1C=^?6K]%%:J*BK)&$IRF[R=PHHHIDA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
